NIH selects Emergex’s T cell vaccine for trials under Project NextGen
The National Institutes of Health (NIH) unit of the National Institute of Allergy and Infectious Diseases (NIAID) has ...
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of synthetic T cell-priming ...
The American Journal of Managed Care23h
Coming Soon: An Off-the-Shelf CAR T Therapy for Myeloma
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
GEN17h
Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma
Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.
NOLA.com10d
Alzheimer's: RORB protein discovery could advance research into selective cell vulnerability
“Our discovery of RORB for these selectively vulnerable cells gives us the opportunity to study in detail exactly why they ...
Medscape33m
European Funding Takes a Lead in Unravelling Long COVID
Europe has announced a €2 million project to research long COVID, following €100 million already invested since 2021. Is all ...
i7d
The lesser-known link between depression and memory problems
Understanding the puzzling link between depression and problems with memory may lead to more powerful treatments for the mood ...
The Advocate10d
Alzheimer's: RORB protein discovery could advance research into selective cell vulnerability
Though researchers can’t pinpoint why individuals have ... which spreads through the brain and drives widespread cell death, resulting in progressive memory loss, dementia and other symptoms.
PharmiWeb16d
OrganaBio Expands Cell and Gene Therapy Donor Base to Include Patients with Lupus, Other Autoimmune Diseases
OrganaBio is responding to sharply rising demand from pharmaceutical companies for donor material from patients with chronic diseases like lupus and psoriatic arthritis, to enable advanced therapies ...